Bausch + Lomb Cor…
USUSDBausch + Lomb Corp (TO:BLCO) — Ophthalmic Goods. Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 2. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.
Über das Unternehmen
- Website
- bausch.com
- Investor Relations
- ir.bausch.com/investor-relations/sec-filings
- Sektor
- Health Care · Ophthalmic Goods
- Hauptsitz
- Rochester, Canada
- CEO
- Brenton L. Saunders
- Mitarbeiter
- 12 900
- Gegründet
- 1853
- Ausstehende Aktien
- 357.17 Mio. Stand 2026-07-22
- Streubesitz
- 45.55 Mio.
- Marktkapitalisierung
- 6.18 Mrd. USD
- Insider
- 87.29%
- Institutionelle Anleger
- 11.14%
- Branche (SIC)
- Ophthalmic Goods
- P/E
- Verlust
- FCF
- 137 Mio. USD
- Schulden
- 5.08 Mrd. USD34 J. FCF
- Gewinne und FCF – für die 12 Monate bis 30.06.2026 (aktueller Bericht des Unternehmens).
- NAV
Beschreibung
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Größte Anteilseigner
| Inhaber | Anteil | Aktien | Berichtsdatum |
|---|---|---|---|
| Icahn Carl C | 0.98% | 3.5 Mio. | 2026-06-30 |
| Oaktree Capital Manageme… | 0.96% | 3.44 Mio. | 2026-06-30 |
| Deutsche Bank AG | 0.96% | 3.42 Mio. | 2026-06-30 |
| Shaw D.E. & Co., Inc. | 0.93% | 3.32 Mio. | 2026-06-30 |
| Davidson Kempner Capital… | 0.88% | 3.16 Mio. | 2026-06-30 |
| Goldentree Asset Managem… | 0.74% | 2.66 Mio. | 2026-06-30 |
| Price (T.Rowe) Associate… | 0.6% | 2.16 Mio. | 2026-06-30 |
| CASPIAN CAPITAL, LP | 0.56% | 2 Mio. | 2026-06-30 |
| Glenview Capital Managem… | 0.54% | 1.92 Mio. | 2026-06-30 |
| Arrowstreet Capital, Lim… | 0.38% | 1.36 Mio. | 2026-06-30 |
| SAUNDERS BRENT L. (Chief… | ≈0.35% | 1.26 Mio. | 2026-08-05 |
| T. Rowe Price High Yield… | 0.23% | 811 242 | 2026-06-30 |
| TR PRICE-Price (T.Rowe)… | 0.13% | 454 220 | 2026-06-30 |
| ELDESSOUKY SAM (Chief Fi… | ≈0.11% | 407 130 | 2026-03-06 |
| ELDESSOUKY OSAMA A (Chie… | ≈0.11% | 393 527 | 2026-08-05 |
| BAILEY AMBROSE ROBERT DO… | ≈0.07% | 264 241 | 2026-08-05 |
| T. ROWE PRICE Inst. INCO… | 0.06% | 214 828 | 2026-06-30 |
| T. ROWE PRICE Intl Fd.S,… | 0.06% | 204 491 | 2026-06-30 |
| HASHAD YEHIA (Officer) | ≈0.05% | 187 350 | 2026-08-05 |
| Unified Series Trust-BAL… | 0.04% | 147 837 | 2026-06-30 |
| Gabelli Healthcare & Wel… | 0.04% | 144 000 | 2026-09-30 |
| BONNEFOY LUC (Officer) | ≈0.03% | 103 801 | 2026-08-05 |
| STEWART ANDREW JUDE (Off… | ≈0.03% | 103 211 | 2026-08-05 |
| ROBERTSON RUSSEL C (Dire… | ≈0.03% | 94 260 | 2026-05-26 |
| PAULSON JOHN A. (Directo… | ≈0.03% | 89 823 | 2026-05-26 |
| BERNIER NATHALIE D (Dire… | ≈0.02% | 85 505 | 2026-05-26 |
| Gabelli Dividend & Incom… | 0.02% | 75 000 | 2026-09-30 |
| T. Rowe Price Credit Opp… | 0.01% | 52 900 | 2026-06-30 |
| Gabelli Asset Fund-The G… | 0.01% | 45 000 | 2026-09-30 |
| Fidelity Rutland Square… | 0.01% | 43 488 | 2026-08-31 |
Mit Google Anmelden